GlassScriptPhysician profile
Colby L Beal
NPI 1598119190
$25,497.56
in general payments reported to CMS, 2019-2025
28 companies · $676 in 2025
The $676 reported for 2025 was more than what 83% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15K · 2021: $1,479 · 2022: $3,920 · 2023: $3,032 · 2024: $920 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465 · Education: $1,820 · Travel and Lodging: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.27 |
| Education | $1,820.00 |
| Travel and Lodging | $342.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $10,253.66 | 2020 | |
| Boston Scientific Corporation | $7,424.50 | 2020-2025 | Intracept, General - Pain Management, Coveredge 32 |
| Painteq LLC | $1,966.06 | 2023-2024 | Painteq |
| Nevro Corp. | $1,439.29 | 2021-2023 | Senza |
| Spr Therapeutics, INC | $1,170.04 | 2021-2023 | Sprint Pns System |
| Relievant Medsystems, INC. | $890.16 | 2022-2023 | Intracept |
| Spinal Simplicity, LLC | $507.22 | 2023-2025 | Ha Minuteman G3-R, Liberty Si |
| Si-Bone, INC. | $407.09 | 2021-2022 | |
| Medtronic, INC. | $365.14 | 2021-2023 | Intellis Adaptivestim |
| Abbott Laboratories | $251.55 | 2021 | |
| Janssen Pharmaceuticals, INC | $188.15 | 2023-2024 | Spravato |
| Abbvie INC. | $121.65 | 2023-2025 | Ubrelvy |
| Nalu Medical, INC. | $108.91 | 2023-2024 | Nalu Neurostimulation System |
| Heron Therapeutics, INC. | $69.07 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.33 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $38.38 | 2023-2024 | Mild Device Kit |
| Lilly USA, LLC | $32.78 | 2025 | Mounjaro, Zepbound |
| Bioventus LLC | $30.02 | 2022 | |
| Amgen INC. | $28.05 | 2025 | Krystexxa |
| Lucid Diagnostics INC. | $27.21 | 2023 | |
| Radius Health, INC. | $21.02 | 2024 | Tymlos |
| Antares Pharma, INC. | $19.40 | 2025 | Xyosted |
| Globus Medical, INC. | $19.38 | 2025 | Vyrsa V1 |
| Stimwave Technologies Incorporated | $16.96 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.39 | 2024 | Euflexxa |
| Merck Sharp & Dohme LLC | $15.14 | 2022 | |
| Organon LLC | $14.58 | 2023 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $14.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colby Beal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.